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Background: Themajority of patients with primary hyperparathyroidism (PHPT) have a single overactive
adenoma. Advances in preoperative imaging and surgical adjuncts have given rise to minimally invasive
parathyroidectomy (MIP), with lower complication rates in comparison with bilateral neck exploration.
Misdiagnosis and undertreatment of multiglandular disease, leading to potentially higher recurrence
rates, remains a concern. This study evaluated risks of long-term (1 year or more) recurrence following
‘targeted’ MIP in PHPT.
Methods: Multiple databases were searched for studies published between January 2004 andMarch 2017,
looking at long-term outcomes (1 year or more) following targeted MIP for PHPT. English-language
studies, with at least 50 patients and a mean follow-up of 1 year, were included.
Results: A total of 5282 patients from 14 studies were included. Overall mean recurrence and cure rates
were 1⋅6 (range 0–3⋅5) and 96⋅9 (95⋅5–100) per cent respectively. Mean follow-up was 33⋅5 (1–145)
months. When intraoperative parathyroid hormone (PTH) measurements were not done, cure rates were
higher (99⋅3 per cent versus 98⋅1 per cent with use of intraoperative PTH measurement; P<0⋅001) and
recurrence rates lower (0⋅2 versus 1⋅5 per cent respectively; P<0⋅001).
Conclusion: Targeted MIP for a presumed single overactive adenoma was associated with very low
recurrence rates, without the need for intraoperative PTH measurement when preoperative imaging
studies were concordant. Targeted MIP should be encouraged.
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Introduction
Primary hyperparathyroidism (PHPT) is a common condi-
tion, with an estimated incidence of one to seven per 1000
adults1. The condition is detected incidentally inmore than
80 per cent of subjects on routine biochemical analysis2,3.
Surgery remains the only curative option.
Parathyroid surgery via an open bilateral four-gland neck
exploration was first performed in 19254 and remained the
standard treatment until the early part of the 21st century.
In experienced hands, this method has a cure rate of at least
95 per cent, with a morbidity rate of less than 3 per cent5,
and does not require any form of preoperative localization
imaging.
It is widely recognized that in over 85 per cent of patients
with PHPT the cause is a single overactive parathyroid
adenoma, often identifiable through preoperative imag-
ing, allowing selective removal5. The two most common
modalities of preoperative localization are sestamibi imag-
ing and high-resolution ultrasonography. A meta-analysis6
examining the value of ultrasound imaging in PHPT
found an overall pooled sensitivity of 76⋅1 per cent and
a positive predictive value of 93⋅2 per cent, although
operator and centre variation was acknowledged7. With
negative localization of a solitary adenoma, the likeli-
hood of multiglandular disease is reported to be up to 30
per cent8,9.
Surgical management of PHPT has evolved over the
past 20 years. Rapid intraoperative parathyroid hormone
(IOPTH) assay10, sestamibi scintigraphy and radio-guided
parathyroidectomy11 have emerged, facilitating the devel-
opment of ‘targeted’ parathyroidectomy techniques based
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Fig. 1 PRISMA diagram for the study
on single-gland excision via unilateral neck exploration.
Various techniques have been described12–15, with a
general consensus that parathyroidectomy is classified
as ‘minimally invasive’ when performed with preop-
erative localization through an incision of less than
2⋅5–3 cm5,12,13.
Targeted minimally invasive parathyroidectomy (MIP)
has been shown in large studies, systematic reviews and
meta-analysis to be highly effective with low complica-
tion rates compared with open bilateral neck exploration
(BNE)14–16. Advantages of MIP include shorter duration
of surgery, lower rates of postoperative hypocalcaemia,
less postoperative pain and a smaller scar17. There are also
potential financial advantages in performing MIP18,19,
with lower operative costs and more rapid hospital
discharge.
The consensus statement published by the European
Society of Endocrine Surgeons (ESES)20 described MIP
as a safe and cost-effective procedure for the treatment
of selected patients with PHPT. In the UK, the National
Institute for Health and Care Excellence (NICE) released
guidelines for minimally invasive video-assisted parathy-
roidectomy (MIVAP)21, stating that ‘current evidence on
the efficacy and safety of MIVAP is adequate to support
the use of this procedure’.
Misdiagnosis and the risk of undertreating multigland
disease, leading to high recurrence rates, neverthe-
less remains a potential shortcoming of this approach.
This systematic review aimed to examine long-term
(1 year or more) recurrence rates following targeted MIP
in PHPT.
Methods
Acquisition of evidence
The PRISMA protocol22 was followed to perform a com-
prehensive literature search using MEDLINE, Embase,
CINAHL, the UK Clinical Trials Gateway and the
US Trials Database between January 2004 and March
2017. The PICO framework23 was used and terms com-
bined with Boolean operators (AND, OR) to refine the
search further.
Two independent reviewers identified all studies that met
the inclusion criteria for full review. References of the
searched studies were evaluated for potential inclusion in
the review. Where possible, contact was attempted with
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Table 1 Summary of included studies
Reference Review period
Study
type
No. of
patients
Sex ratio
(M : F) Age (years)*
Mean recurrence
rate (%)*
Mean cure
rate (%)*
Follow-up
(months)*
Chen et al.26 1990–2004 Retrospective 188 n.d. 60(3) 1⋅1 99⋅0 48
Cohen et al.27 1999–2004 Retrospective 139 32 : 107 60(15) (16-88) 0⋅0 98⋅6 15(12) (3–38)
Barczynski et al.20 2000–2006 Prospective 115 18 : 97 57⋅1(12⋅2) 0⋅9 98⋅3 28(10) (6–42)
Mihai et al.32 2001–2006 Prospective 150 46 : 104 60(16) (17–89) 0⋅0 99⋅3 15(10) (3–48)
Fouquet et al.33 2001–2008 Prospective 200 35 : 165 63⋅1 (13–87) 0⋅5 98⋅0 13(13) (6–72)
Venkat et al.34 2004–2009 Prospective 200 51 : 149 58⋅7(11⋅9) (13–88) 2⋅5 97⋅0 37(19) (6–72)
Barczyn´ski et al.28 2003–2012 Retrospective 455 57 : 398 54⋅7(15⋅6) (18–82) 2⋅3 99⋅6 43(16) (12–112)
Chow et al.29 2002–2012 Retrospective 105 29 : 76 61⋅5(14⋅6) 0⋅0 n.d. 56⋅9
Norlén et al.31 1990–2013 Retrospective 2531 593 : 1938 61⋅8(13⋅9) 1⋅8 95⋅5 78 (1–24)†
Day et al.35 2003–2013 Prospective 556 147 : 409 61⋅1(13⋅4) 2⋅0 97⋅3 44 (1–145)
Yang et al.30 2008–2012 Retrospective 115 37 : 78 46 (28–57)† 0⋅9 99⋅1 24
Nijhuis et al.37 2000–2013 n.d. 114 n.d. n.d. 3⋅5 96⋅5 34†
Thier et al.36 1989–2010 Prospective 292 58 : 234 66†(i.q.r. 57–75) 0⋅3 1 year: 98⋅5 60 (1–180)†
5 years: 99⋅4
10 and 15 years: 100
Kim et al.11 2000–2012 Retrospective 122 28 : 94 50⋅8(13) 0⋅0 99⋅2 45⋅5(42⋅2)
*Values are mean(s.d.) (range) unless indicated otherwise; †values are median (range) unless indicated otherwise. n.d., Not documented.
authors to verify data that were not clearly described or to
confirm that specific data were not available from the study.
The study included all articles published between January
2004 and March 2017 that reported MIP alone or com-
parison with BNE, involving at least 50 patients, where
recurrence rates were documented and mean follow-up
was at least 1 year. Parathyroidectomy was considered
minimally invasive if the authors documented incision of
3 cm or less, or if MIP was clearly stated. Only articles
published in English were considered, and no age limits
were set.
To analyse the best available data focusing on long-term
(follow-up of at least 1 year) recurrence and cure rates, the
inclusion criterion for centres performing MIP regularly
(at least 50 patients per annum) was set. This was done to
minimize skewing of data from ‘low-volume’ centres and
small case series.
Study quality and levels of evidence
The quality of studies and risk of bias were assessed by
two reviewers. All studies included in the review were
non-randomized, and therefore the Methodological Index
for Non-Randomized Studies (MINORS) tool24 was
used. This tool assessed non-randomized studies on the
following criteria: clearly stated aims, inclusion of con-
secutive patients, prospective data collection, appropriate
endpoints, unbiased evaluation of endpoints, appropriate
duration of follow-up and loss to follow-up no more than
5 per cent. For comparative studies, further criteria were
assessed: whether the control group underwent a standard
intervention, the use of contemporary groups, baseline
equivalence of the groups, prospective calculation of the
sample size and statistical analysis adapted to the study
design.
To ascertain the level of evidence of the included
studies, the Oxford Centre for Evidence-based Medicine
(OCEM)25 guidelines were employed.
Outcomes
The primary outcome was recurrence rate, defined as the
rate of hypercalcaemia occurring after 6months of normo-
calcaemia following parathyroidectomy.
Secondary outcomes were: cure rate (defined as normo-
calcaemia persisting for more than 6months after surgery),
type of MIP performed, use of IOPTHmeasurements and
postoperative complication rate.
When analysing IOPTH use and non-use during MIP,
the studies were divided into those that included only
patients who exhibited positive preoperative concordant
imaging (PC cohort) and those that included a het-
erogeneous cohort (H cohort: 1–2 image-positive or
image-negative patients).
Statistical analysis
GraphPad Prism® version 7.0d (GraphPad Software, La
Jolla, California, USA) was used for statistical analysis,
and Microsoft Excel® version 16.12 (Microsoft, Redmond,
Washington, USA) for data handling. The statistical sig-
nificance of categorical variables was determined with
Fisher’s exact test. P< 0⋅050 was considered statistically
significant.
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Table 2 Recurrence and cure rates according to patient cohort and intraoperative parathyroid hormone measurement
IOPTH measurement No IOPTH measurement Overall
Recurrence
rate (%)
Cure
rate (%)
No. of
patients
Recurrence
rate (%)
Cure
rate (%)
No of
patients
Recurrence
rate (%)
Cure
rate (%)
Preoperative concordant
imaging cohort
2⋅0 99⋅5 570 0⋅2 99⋅3 2786 0⋅5 99⋅3
Heterogeneous cohort 1⋅3 95⋅6 1502 0⋅0 99⋅2 122 1⋅7 97⋅7
Overall 1⋅5 98⋅1 2072 0⋅2 99⋅3 2908
IOPTH, intraoperative parathyroid hormone.
Results
Study identification
The initial literature search yielded a total of 252 studies,
of which 1411,20,26–37 met the inclusion criteria (Fig. 1). All
studies were observational and included a total of 5282
patients who had targeted MIP for PHPT. There was a
female preponderance of 3⋅4 : 1 and the overall mean age
was 58⋅9 years (Table 1).
Quality of studies and levels of evidence
Of the 14 studies, seven were retrospective11,26–31, six
involved collection of prospectively identified items20,32–36
and one37 did not clarify the type of study. The median
MINORS score was 10 of 16 (mean 9⋅8, range 6–14)
for all studies, and the median of the four comparative
studies11,20,26,28 was 15 of 24 (mean 14⋅25, range 10–17).
According to the OCEM criteria, all of the included
studies were classified as individual cohort studies and were
therefore classified as having level 2b evidence.
Outcomes
The overall mean recurrence rate for the 5282 patients
was 1⋅6 (range 0–3⋅5) per cent, and the overall cure rate
96⋅9 (95⋅5–100) per cent. The overall mean duration of
follow-up for the studies includedwas 33⋅5 (1–145)months
(Table 1).
All studies defined cure as normalization of serum cal-
cium levels, and all recorded serum calcium levels at each
follow-up appointment. All but three studies26,31,37 also
measured postoperative serum PTH levels routinely.
All studies used the widely accepted definition of ‘disease
recurrence’ as hypercalcaemia after 6months of proven
normocalcaemia following initial surgery.
The most common type of surgery performed was the
open MIP technique26,27,29–32,34–37, but other approaches
included MIVAP20,28, minimally invasive radio-guided
parathyroidectomy11 and a totally endoscopic MIP
technique33. When reported, studies had incision lengths
of less than 3 cm, whereas studies that did not report on
incision length stated that their procedure was ‘minimally
invasive’ or a ‘focused/lateral exploration’.
Four studies11,29,31,32 with a total of 2908 patients per-
formed targeted MIP without IOPTHmeasurements, and
nine studies20,26–28,30,33–36 carried out targeted MIP with
IOPTHmeasurements in 2072 of the patients. One study37
made no reference to the use of this test, so was not
included in the analysis. Five studies28–32 included only
patients with positive, concordant preoperative localiza-
tion studies on at least two different imaging modali-
ties, seven11,20,27,33–36 included patients regardless of imag-
ing findings, and two26,37 did not report on imaging
findings.
When IOPTH measurement was not done during MIP,
overall mean cure rates were higher (99⋅3 per cent ver-
sus 98⋅1 per cent when IOPTH measurement was done;
P< 0⋅001) and recurrence rates were lower (0⋅2 versus 1⋅5
per cent respectively; P< 0⋅001) (Table 2).
An overall complication rate of 4⋅4 per cent in 4010
patients was reported in nine studies20,27–34, whereas
five11,26,35–37 did not report complication rates. Transient
and permanent postoperative hypocalcaemia rates were
1⋅6 and 0⋅05 per cent respectively. Temporary recurrent
laryngeal nerve (RLN) palsy occurred in 1⋅1 per cent and
permanent RLN palsy in 0⋅3 per cent of the 4010 patients.
Complications are summarized in Table 3.
There were significant differences in how complications
were defined and reported. In terms of RLN palsy, four
studies20,28,31,40 routinely used laryngoscopy after surgery,
one study29 used laryngoscopy in patients with postop-
erative dysphonia, and another study30 explicitly stated
that laryngoscopy was not used. The remaining publica-
tions did not comment on postoperative laryngoscopy.
The definition of hypocalcaemia also varied, from a
serum calcium level lower than 2mmol/l28 to 1⋅95mmol/l
or less30, whereas other studies did not define cut-off
levels.
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Table 3 Complications
No. of complications
(n=176)
Temporary RLN palsy seen on
laryngoscopy
35 (19⋅9)
Transient hypocalcaemia defined as
<2mmol/l
23 (13⋅1)
Transient hypocalcaemia defined as
≤1⋅95mmol/l
23 (13⋅1)
Hypocalcaemia (NOS) 22 (12⋅5)
Temporary hypoparathyroidism defined as
hypocalcaemia (NOS) requiring calcium
or vitamin D supplementation, resolving
within 6months
17 (9⋅7)
Other complication (NOS) 13 (7⋅4)
Permanent RLN palsy seen on
laryngoscopy
11 (6⋅3)
Wound haematoma requiring return to
theatre for evacuation
8 (4⋅5)
Temporary RLN palsy (laryngoscopy use
not documented)
7 (4⋅0)
Wound infection 4 (2⋅3)
Myocardial infarction 2 (1⋅1)
Temporary RLN palsy (selective use of
laryngoscopy)
2 (1⋅1)
Permanent hypoparathyroidism defined
as hypocalcaemia (NOS) requiring
calcium or vitamin D supplementation,
persisting after 6months
2 (1⋅1)
Mild neck swelling, managed
conservatively
1 (0⋅6)
Transient hypercalcaemia returning to
normal
1 (0⋅6)
Wound haematoma, managed
conservatively
1 (0⋅6)
Permanent RLN palsy (laryngoscopy use
not documented)
1 (0⋅6)
Cerebrovascular accident 1 (0⋅6)
Permanent RLN palsy (selective use of
laryngoscopy)
1 (0⋅6)
30-day mortality not related to surgery 1 (0⋅6)
Values in parentheses are percentages. RLN, recurrent laryngeal nerve;
NOS, not otherwise specified.
Discussion
This systematic review has indicated that, despite varia-
tions in technique, targeted MIP was associated with low
long-term (at least 1 year) recurrence rates of only about
1⋅5 per cent.
Overall recurrence rates were lowest and cure rates high-
est in studies that included patients where there was pos-
itive, concordant preoperative localization. Interestingly,
the analysis suggested that recurrence and cure rates were
better when IOPTHmeasurements were not used. As indi-
cated in Table 2, this appeared to reflect use of MIP without
routine IOPTH measurement in patients with concordant
imaging. IOPTH measurement seemed to be used more
frequently in non-concordant or image-negative patients.
Two reports38,39 relating toMIPwere not included in this
systematic review as they did not fulfil the inclusion crite-
ria (mean duration of follow-up not documented). These
studies reported a median follow-up of 9 (range 0–116)
months. The first study38 investigated whether MIP was
associated with a higher recurrence rate than BNE, and
the second39 considered variables that might predict recur-
rence in parathyroidectomy for PHPT. In both stud-
ies, Kaplan–Meier curves were constructed to determine
disease-free estimates for MIP and BNE. No statistically
significant differences were found between MIP and open
parathyroidectomy in either study (P= 0⋅55 and P= 0⋅59
respectively).
A meta-analysis14 of studies comparing focused parathy-
roidectomy with conventional BNE found that recurrence
(odds ratio (OR) 1⋅08, 95 per cent c.i. 0⋅59 to 2⋅00;P= 0⋅80)
and failure (OR 0⋅88, 0⋅58 to 1⋅34; P= 0⋅56) rates were
comparable. Complication rates were significantly lower in
the focused parathyroidectomy arm (OR 0⋅35, 0⋅15 to 0⋅84;
P= 0⋅02), predominantly related to a lower risk of tran-
sient hypocalcaemia (OR 0⋅36, 0⋅14 to 0⋅90; P= 0⋅03). The
present review is consistent with these findings, with a 1⋅6
per cent temporary and 0⋅05 per cent permanent postoper-
ative hypocalcaemia rate after MIP.
This review also demonstrated the overall complication
rate to be low (4⋅4 per cent in 4010 patients), and similar
to values reported by previous large studies15,40 involving
BNE, together with similar rates of permanent and tempo-
rary recurrent laryngeal nerve palsy (0⋅3 and 1⋅1 per cent
respectively). The lack of postoperative laryngoscopy in the
present review and in other studies, however, may mean
that the true rate of recurrent nerve palsy is underesti-
mated. Similar consideration applies to rates of postopera-
tive hypocalcaemia, owing to the different cut-off levels.
This systematic review analysed 14 level 2b studies with
a median MINORS score of 10 (mean 9⋅8), indicating
evidence of fair quality. However, its main limitation was
the lack of uniformity in the presentation and reporting of
data by the individual studies. This is a widely recognized
and inherent problem of collating data from observational
studies.
Despite these shortcomings, targetedMIP in the surgical
management of patients with a presumed single overactive
parathyroid adenoma is a safe technique that provides
long-term cure. The review also suggests that MIP is
effective without intraoperative hormone estimations in
patients with preoperative concordant imaging.
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